Argo Blockchain
ARBK
Strategy
MSTR
BTCS Inc
BTCS
Canaan
CAN
Bit Origin
BTOG
US Stock MarketDetailed Quotes
IKT Inhibikase Therapeutics
- 2.3500
- +0.1200+5.38%
Close Feb 14 16:00 ET
- 2.4300
- +0.0800+3.40%
Post 20:01 ET
163.00MMarket Cap-0.75P/E (TTM)
2.3800High2.2100Low122.53KVolume2.2100Open2.2300Pre Close284.74KTurnover0.99%Turnover RatioLossP/E (Static)69.36MShares4.200052wk High-293.75P/B29.16MFloat Cap1.120052wk Low--Dividend TTM12.41MShs Float70.8000Historical High--Div YieldTTM7.62%Amplitude0.7900Historical Low2.3230Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Inhibikase Therapeutics Stock Forum
4 mins ago
Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability!
Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
Positive
Secured significant financing of up to $275 million, including $110 million immediate private placement
Received FDA Study May Proceed letter for IkT-001Pro PAH trial
High trial completion rate with 120 of 126 patients completing the Phase 2 201 Trial
Negative
Increased net loss to $5.8 million in Q3 2024 from $4.6 million in Q3 2023
R&D expenses incr...
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-SP IKT HOLDINGS LLC(8.69%),SP Soleus Holdings LLC(8.69%)
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Soleus Private Equity Fund III, L.P.(9.99%),Soleus Private Equity GP III, LLC(9.99%), etc.
SEC· Oct 25 17:52 )))
Inhibikase Therapeutics | 3: Initial statement of beneficial ownership of securities-10% Owner Sands Capital Life Sciences Pulse Fund II, L.P.
Inhibikase Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Sands Capital Life Sciences Pulse Fund II, L.P.(16.3%),Sands Capital Ventures, LLC(16.3%), etc.
No comment yet